ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2013
Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Trial
- Cytotoxic Virulence Predicts Mortality in Nosocomial Pneumonia Due to Methicillin-Resistant Staphylococcus aureus.The Journal of infectious diseases · 2015Trial
- Staphylococcus aureus With Reduced Vancomycin Susceptibility: Diagnostic Challenges in Clinical Settings.Cureus · 2026Review
- A Highly Efficacious Electrical Biofilm Treatment System for Combating Chronic Wound Bacterial Infections.Advanced materials (Deerfield Beach, Fla.) · 2023Article
- MRSA compendium of epidemiology, transmission, pathophysiology, treatment, and prevention within one health framework.Frontiers in microbiology · 2022Review
- Vancomycin Use in Children and Neonates across Three Decades: A Bibliometric Analysis of the Top-Cited Articles.Pathogens (Basel, Switzerland) · 2021Review
- Review
- Identifying the effect of vancomycin on health care-associated methicillin-resistant Staphylococcus aureus strains using bacteriological and physiological media.GigaScience · 2021Article
- Molecular Confirmation of Vancomycin-ResistantInternational journal of microbiology · 2021Article
- A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Bacteriophage-Antibiotic Combination Strategy: an Alternative against Methicillin-Resistant Phenotypes of Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2020Article
- High sensitivity versus low level of vancomycin needs to be concern for another alternative anti- Staphylococcus aureus as the first- line antibiotic.Acta bio-medica : Atenei Parmensis · 2019Article
- Low concentrations of acetic and formic acids enhance the inactivation of Staphylococcus aureus and Pseudomonas aeruginosa with pulsed electric fields.BMC microbiology · 2019Article
- Reporting elevated vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus: consensus by an International Working Group.Future microbiology · 2019Article
- Mode of action of the antimicrobial peptide Mel4 is independent of Staphylococcus aureus cell membrane permeability.PloS one · 2019Article
- Semi-Automated Visualization and ANalysis of Trends: A "SAVANT" for Facilitating Antimicrobial Stewardship Using Antistaphylococcal Resistance and Consumption as a Prototype.Open forum infectious diseases · 2018Article
- Mouse model of hematogenous implant-relatedProceedings of the National Academy of Sciences of the United States of America · 2017Article
- Synergistic antibacterial effects of herbal extracts and antibiotics on methicillin-resistant Staphylococcus aureus: A computational and experimental study.Experimental biology and medicine (Maywood, N.J.) · 2017Article
- A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations.Clinical pharmacokinetics · 2017Article
- Dracorhodin Perochlorate attenuates Staphylococcus aureus USA300 virulence by decreasing α-toxin expression.World journal of microbiology & biotechnology · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
For more than 4 decades, vancomycin has been the antibiotic of choice for methicillin-resistant Staphylococcus aureus (MRSA) infections. Recently, infections due to isolates with high but susceptible vancomycin minimum inhibitory concentrations have been associated with additional treatment failures and patient mortality. These poorer outcomes may in part be explained by the inability of attaining appropriate vancomycin levels in these patients. However, assumptions that these poor outcomes are solely due to failure to achieve optimal serum levels of vancomycin are premature. The availability of effective alternatives further erodes the position of vancomycin as first-line therapy. The emergence of resistance and cost considerations, however, favor a more measured approach when using alternative antimicrobials. Collectively, the current available data suggest that the optimal therapy for MRSA infections remains unclear. In the absence of further data, the Infectious Diseases Society of America guidelines remain relevant and inform clinicians of best practice for treating patients with MRSA infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.